New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: A pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials

Neuro-Oncology

Volumn 15, Issue 11, 2013, Pages 1568-1579

  Gorlia, M Thierry ^a   Wu, Wenting ^b   Wang, Meihua ^c   Baumert, Brigitta G ^d,e   Mehta, Minesh ^c   Buckner, Jan C ^b   Shaw, Edward ^c   Brown, Paul ^b   Stupp, Roger ^f   Galanis, Evanthia ^b   Lacombe, Denis ^a   Van Den Bent, Martin J ^g  

^a EORTC DATA CENTER   (Belgium)

^b North Central Cancer Treatment Group Rochester   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MediClin Robert Janker Klinik   (Germany)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Low grade glioma; Predictive accuracy; Prognostic factors

Indexed keywords

ARTICLE; ASTROCYTOMA; CALCULATOR; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER; FOLLOW UP; GLIOMA; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; NEUROLOGIC DISEASE; NOMOGRAM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALIDITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SURVIVAL PREDICTION; TUMOR VOLUME;

LOW-GRADE GLIOMA; PREDICTIVE ACCURACY; PROGNOSTIC FACTORS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; YOUNG ADULT;

EID: 84891870744     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not117     Document Type: Article

References (19)

1. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
2. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase 3 trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902-1909.
3. van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Timefor randomized studies.NatRev Neurol. 2010;6(12):695-701.
4. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organisation For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66(6):545-551.
5. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol. 2010;120(3):297-304.
6. PignattiF,vandenBentM,CurranD,et al.Prognostic factors for survival inadult patientswithcerebral low-gradeglioma.JClinOncol.2002;20(8):2076-2084.
7. Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: A report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011;81(1):218-224.
8. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2227.
9. Shaw E, Wang M, Coons S, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065-3070.
10. Harrell FE, Jr, Lee KL. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
11. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
12. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11(16):2093-2109.
13. Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics. 2000;56(1):249-255.
14. Heinze G, Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed. 2003;71(2):155-163.
15. Dunkler D, Michiels S. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer. 2007;43(4):745-751.
16. Slud EV, Byar DPA. Comparison of reflected versus test-based confidence intervals for the median survival time, basedoncensored data. Biometrics. 1984;40(3):587-600.
17. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42(15):2499-2450.
18. van den BentMJ,Dubbink HJ,Marie Y, et al. IDH1 and IDH2mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organisation for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-1604.
19. Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys. 2004;59(1): 117-125.